M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

Crescent Biopharma is advancing a drug its CEO claims is “purpose-built” to be a perfected version of Summit Therapeutics’ ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

The company's leading candidate, ivonescimab, is a lung cancer drug. Back in September, Summit published data from a phase III clinical trial in which ivonescimab was benchmarked against Merck's ...

Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...

The latest update is out from Summit Therapeutics ( (SMMT) ).

Crescent Biopharma has landed a Nasdaq listing in a reverse merger with GlycoMimetics and secured $200 million to support its pursuit of the white-hot PD-1xVEGF bispecific opportunity. GlycoMimetics ...

Summit's leading candidate, ivonescimab, has delivered solid results in clinical trials and has already been approved in China to treat some forms of cancer. Summit entered into an agreement with ...

The stock has risen over 600% since the end of 2023, thanks to surprisingly positive trial results for a cancer therapy called ivonescimab. The stock market has been pushing up Summit's stock ...